ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA
Status:
COMPLETED
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
For the last years the aim of the management of ulcerative colitis (UC) has become more ambitious including not only clinical remission but also the achievement of biological remission, endoscopic and histological healing, which are associated with less flares, hospitalizations and surgeries. About 50% of the patients with UC followed in routine are treated by 5-aminosalicylate acid (5-ASA) (oral and/or topical). The aim of the study is to describe the different levels of remission (clinical, endoscopic, histological) in UC patients treated only by 5-ASA, that report to be in clinical remission during a routine follow-up visit. The factors associated with different levels of remission (demographic, 5-ASA regimen, biologic, endoscopic, histologic) will be studied. Adherence and quality of life will be examined through patient questionnaires.
Phase:
PHASE4
Details
Lead Sponsor:
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW